Humanigen has announced that its antibody lenzilumab increased the likelihood of survival among certain Black and African American patients with COVID-19.
Lenzilumab is a novel, first in-class product “that binds to and neutralizes granulocyte-macrophage colony-stimulating factor,” according to a company press release.
The data on lenzilumab are from the phase 3 LIVE-AIR trial, which enrolled 520 adults from 29 sites in the United States and Brazil who experienced blood oxygen saturation of 94% or less; or needed low-flow supplemental oxygen, high-flow oxygen support or noninvasive